PMS-CLOBETASOL 0.05 %
CLOBETASOL PROPIONATE : 0.05 % · DIN 02309548 · PHARMASCIENCE INC
Health Canada status: CANCELLED POST MARKET
What is PMS-CLOBETASOL?
PMS-CLOBETASOL 0.05 % contains CLOBETASOL PROPIONATE : 0.05 %. It is listed in the Health Canada Drug Product Database under DIN 02309548, held by PHARMASCIENCE INC, supplied as OINTMENT for TOPICAL administration. Health Canada currently lists it as cancelled post market, status dated 02-Oct-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PMS-CLOBETASOL used for?
Topical therapy of recalcitrant corticosteroid-responsive dermatoses, including severe cases of psoriasis (excluding widespread plaque psoriasis) and eczematous dermatitis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02309548 |
|---|---|
| Brand name | PMS-CLOBETASOL |
| Generic / active ingredient | CLOBETASOL PROPIONATE : 0.05 % |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 0.05 % |
| Dosage form | OINTMENT |
| Route of administration | TOPICAL |
| Schedule | Prescription |
| ATC code | D07AD01 CLOBETASOL |
| AHFS class | 92:92.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 02-Oct-2025 |
| Original market date | 2008-09-26 00:00:00 |
How is it administered?
Apply a thin layer to affected area twice daily. Limit treatment to 2 consecutive weeks. Do not exceed 50 g per week. Discontinue if no response after 1 week or once lesion heals.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15° - 30°C.
How is it supplied?
Tubes of 15 and 50 grams.
Contraindications
Infected skin lesions (without anti-infectives); fungal/viral/tuberculous skin infections; rosacea; acne vulgaris; peri-oral dermatitis; pregnancy and lactation; hypersensitivity to corticosteroids.
Warnings and precautions
Not for ophthalmic use. Risk of HPA axis suppression, Cushing's syndrome, and systemic effects if used over large areas or for prolonged periods. Do not exceed 50 g/week.
What can be used instead?
Other Canadian products sharing ATC code D07AD01 CLOBETASOL. 20 of 40 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CLOBEX SHAMPOO | 0.05 % | SHAMPOO | GALDERMA CANADA INC | MARKETED | DIN 02256371 |
| CLOBEX SPRAY | 0.05 % | SPRAY | GALDERMA CANADA INC | MARKETED | DIN 02299739 |
| DERMOVATE CREAM | 0.05 % | CREAM | TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC. | MARKETED | DIN 02213265 |
| DERMOVATE OINTMENT | .05 % | OINTMENT | TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC. | MARKETED | DIN 02213273 |
| DERMOVATE SCALP APPLICATION | .05 % | SOLUTION | TAROPHARMA, A DIVISION OF TARO PHARMACEUTICALS INC. | MARKETED | DIN 02213281 |
| JAMP CLOBETASOL SPRAY | 0.05 % | SPRAY | JAMP PHARMA CORPORATION | MARKETED | DIN 02534665 |
| MYLAN-CLOBETASOL CREAM | 0.05 % | CREAM | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02024187 |
| MYLAN-CLOBETASOL OINTMENT | 0.05 % | OINTMENT | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02026767 |
| MYLAN-CLOBETASOL SCALP APPLICATION | 0.05 % | LOTION | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02216213 |
| ODAN CLOBETASOL SPRAY | 0.05 % | SPRAY | ODAN LABORATORIES LTD | MARKETED | DIN 02490706 |
Who else supplies CLOBETASOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CLOBETASOL appears in 85 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.